Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 28Leukemia 8Recurrence 6Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 2Solid Tumors 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies 1Aortic aneurysm, familial thoracic 4 1

Interventions

Cyclophosphamide 62fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 44ruxolitinib 41Tacrolimus 41Busulfan 40Mycophenolic Acid 36Whole-Body Irradiation 32Antilymphocyte Serum 29Methotrexate 27Cyclosporine 27fludarabine 24Melphalan 19Filgrastim 19Radiotherapy 15Methylprednisolone 13thymoglobulin 12Stem Cell Transplantation 12Etoposide 12Cord Blood Stem Cell Transplantation 12Azacitidine 12Sirolimus 11Flow Cytometry 1011-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 10Psychiatric Rehabilitation 9Decitabine 9Specimen Handling 8Prednisone 8Cytarabine 8navitoclax 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × quizartinib × Clear all
NCT00462761 2020-05-11

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Daiichi Sankyo

Phase 1 Completed
76 enrolled 12 charts
MyeloidOther hematologic neoplasm

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡